Daclizumab use in patients with pediatric multiple sclerosis

Archives of Neurology

Volumn 69, Issue 1, 2012, Pages 78-81

  Gorman, Mark P ^a,b   Tillema, Jan Mendelt ^d   Ciliax, Annika M ^c   Guttmann, Charles R G ^c   Chitnis, Tanuja ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; DACLIZUMAB; GLATIRAMER; INTERFERON; METHYLPREDNISOLONE; NATALIZUMAB;

ADOLESCENT; ADULT; ADVERSE OUTCOME; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE ACTIVITY; DISEASE COURSE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION; LEUKOPENIA; MALE; MONOTHERAPY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; RISK REDUCTION; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES;

EID: 84855574271     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.581     Document Type: Article

References (18)

1. Ghezzi A; Immunomodulatory Treatment of Early Onset MS (ITEMS) Group. Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study. Neurol Sci. 2005;26(suppl 4):S183-S186.
2. Yeh EA, Waubant E, Krupp LB, et al. Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol. 2011;68(4):437-444.
3. Huppke P, Stark W, Zürcher C, Huppke B, Brück W, Gärtner J. Natalizumab use in pediatric multiple sclerosis. Arch Neurol. 2008;65(12):1655-1658.
4. Makhani N, Gorman MP, Branson HM, Stazzone L, Banwell BL, Chitnis T. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology. 2009;72 (24):2076-2082.
5. Sivieri S, Ferrarini AM, Gallo P. Multiple sclerosis: IL-2 and sIL-2R levels in cerebrospinal fluid and serum: review of literature and critical analysis of ELISA pitfalls. Mult Scler. 1998;4(1):7-11. (Pubitemid 28077429)
6. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A. 2004;101(23):8705-8708. (Pubitemid 38745835)
7. Rose JW, Watt HE, White AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol. 2004;56(6): 864-867. (Pubitemid 39578450)
8. Bielekova B, Howard T, Packer AN, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol. 2009;66(4):483-489.
9. Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology. 2007;69(8):785-789. (Pubitemid 47300936)
10. Wynn D, Kaufman M, Montalban X, et al CHOICE Investigators. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, doubleblind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010; 9(4):381-390.
11. Phase III clinical trial using daclizumab for relapsing-remitting multiple sclerosis initiated. Expert Rev Clin Immunol. 2010;6(4):509.
12. Krupp LB, Banwell B, Tenembaum S; International Pediatric MS Study Group. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology. 2007;68(16)(suppl 2):S7-S12. (Pubitemid 46626001)
13. Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009; 66(1):54-59.
14. Ghezzi A, Pozzilli C, Grimaldi LM, et al. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology. 2010;75(10):912-917.
15. Zhao, Traboulsee A, Petkau AJ, Li D. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis. Neurology. 2008;70 (13, pt 2):1092-1097 Y. (Pubitemid 351464765)
16. Di Filippo S. Anti-IL-2 receptor antibody vs polyclonal anti-lymphocyte antibody as induction therapy in pediatric transplantation. Pediatr Transplant. 2005; 9(3):373-380. (Pubitemid 40780371)
17. Gallagher M, Quinones K, Cervantes-Castañeda RA, Yilmaz T, Foster CS. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol. 2007;91(10):1341-1344. (Pubitemid 47492870)
18. Ali EN, Healy BC, Stazzone LA, Brown BA, Weiner HL, Khoury SJ. Daclizumab in treatment of multiple sclerosis patients. Mult Scler. 2009;15(2):272-274.